^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:CH4987655 (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Clin Cancer Res
    Title:

    Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

    Excerpt:
    Our findings show that RO4987655 has clinical activity in patients with…KRAS-mutated NSCLC…The promising CBR ≥ 8 weeks of 56% (10/18; 2 PR/8 SD) with the MEK inhibitor RO4987655 as single agent in 18 patients with KRAS-mutated NSCLCs in third-line and significant metabolic responses demonstrated...
    DOI:
    10.1158/1078-0432.CCR-14-0341